$QURE News

Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75

Wolfe Research Upgrades uniQure to Outperform, Announces $65 Price Target

Barclays Maintains Overweight on uniQure, Lowers Price Target to $60

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

UniQure (NASDAQ:QURE) Rises on Pipeline Progress Despite Wider Q2 Loss

uniQure Q2 EPS $(1.22) Misses $(0.82) Estimate, Sales $5.800M Beat $5.467M Estimate

HC Wainwright & Co. Maintains Buy on uniQure, Raises Price Target to $80

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances

Mizuho Maintains Outperform on uniQure, Raises Price Target to $68

uniQure Announces Pricing of Upsized $225 Million Public Offering

uniQure Announces $150 Million Proposed Public Offering

QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy

QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework Risk

uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 Update

uniQure (QURE) Is Up 67.9% After FDA Backs AMT-130 Data For Accelerated Approval Path

uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy